Literature DB >> 22068810

Further studies on delineating thyroid-stimulating hormone (TSH) reference range.

M Zarković1, J Cirić, B Beleslin, S Cirić, P Bulat, D Topalov, B Trbojević.   

Abstract

The aim of the study was to evaluate thyroid-stimulating hormone (TSH) concentration in a reference group and to compare it with the TSH in subjects with high probability of thyroid dysfunction. The study population consisted of 852 subjects. The reference group consisting of 316 subjects was obtained by the exclusion of the subjects having thyroid disease, taking thyroid influencing drugs, having increased thyroid peroxidase (TPO) antibodies, or having abnormal thyroid ultrasound. 42 high probability of thyroid dysfunction subjects were defined by the association of increased TPO antibody concentration, changed echogenicity, and changed echosonographic structure of thyroid parenchyma. In the reference group TSH reference range was 0.45 mU/l (95% CI 0.39-0.56 mU/l) to 3.43 mU/l (95% CI 3.10-4.22 mU/l). To distinguish reference and high probability of thyroid dysfunction group a TSH threshold was calculated. At a threshold value of 3.09 mU/l (95% CI 2.93-3.38 mU/l), specificity was 95% and sensitivity 38.1%. Using 2 different approaches to find upper limit of the TSH reference range we obtained similar results. Using reference group only a value of 3.43 mU/l was obtained. Using both reference group and subjects with the high probability of thyroid dysfunction we obtained 95% CI for the upper reference limit between 2.93 and 3.38 mU/l. Based on these premises, it could be argued that conservative estimate of the TSH upper reference range should be 3.4 mU/l for both sexes. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068810     DOI: 10.1055/s-0031-1291273

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Cognitive functioning and quality of life in patients with Hashimoto thyroiditis on long-term levothyroxine replacement.

Authors:  Marina Djurovic; Alberto M Pereira; Johannes W A Smit; Olga Vasovic; Svetozar Damjanovic; Zvezdana Jemuovic; Dragan Pavlovic; Dragana Miljic; Sandra Pekic; Marko Stojanovic; Milika Asanin; Gordana Krljanac; Milan Petakov
Journal:  Endocrine       Date:  2018-06-29       Impact factor: 3.633

2.  Reference Intervals for Thyroid-Associated Hormones and the Prevalence of Thyroid Diseases in the Chinese Population.

Authors:  Yutong Zou; Danchen Wang; Xinqi Cheng; Chaochao Ma; Songbai Lin; Yingying Hu; Songlin Yu; Liangyu Xia; Honglei Li; Yicong Yin; Huaicheng Liu; Dianxi Zhang; Kui Zhang; Xiaolan Lian; Tengda Xu; Ling Qiu
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

3.  TSH cut off point based on depression in hypothyroid patients.

Authors:  A Talaei; N Rafee; F Rafei; A Chehrei
Journal:  BMC Psychiatry       Date:  2017-09-07       Impact factor: 3.630

4.  Follicular fluid thyroid autoantibodies, thyrotropin, free thyroxine levels and assisted reproductive technology outcome.

Authors:  Sanja Medenica; Eliana Garalejic; Biljana Arsic; Biljana Medjo; Dragana Bojovic Jovic; Dzihan Abazovic; Rade Vukovic; Milos Zarkovic
Journal:  PLoS One       Date:  2018-10-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.